Additionally, KIF4A has notable pan-cancer traits, being overexpressed and linked to poor prognosis in numerous malignancies like endometrial [4, 63], prostate [5, 65], glioma [7, 8], hepatocellular [71, 74], colorectal [10, 43], breast [27, 31], and lung cancers [38, 93], meaning targeting strategies could benefit a wide range of cancer patients. Here, KIF4A is linked to central nervous system cancer.